Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N P Bailey

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
British Journal of Cancer|January 19, 2000
Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapyP J Barrett-Lee, N P Bailey, M E O'Brien, et al.
British Journal of Cancer|January 1, 1997
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancerN Siddiqui, A V Boddy, H D Thomas, et al.
Hematological Oncology|December 1, 1996
A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma GroupG M Smith, J A Child, M H Cullen, et al.
Seminars in Oncology|October 1, 1995
Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactionsA H Calvert, A Boddy, N P Bailey, et al.
Seminars in Oncology|October 1, 1994
Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation studyA H Calvert, M J Lind, S Ghazal-Aswad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumorsI Rafi, A V Boddy, J A Calvete, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
A phase I and pharmacokinetic study of LY231514, the multitargeted antifolateA C McDonald, P A Vasey, L Adams, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 1998
Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma GroupN P Bailey, N S Stuart, E M Bessell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancerM J Lind, S Ghazal-Aswad, L Gumbrell, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
British Journal of Cancer|January 19, 2000
Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapyP J Barrett-Lee, N P Bailey, M E O'Brien, et al.
British Journal of Cancer|January 1, 1997
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancerN Siddiqui, A V Boddy, H D Thomas, et al.
Hematological Oncology|December 1, 1996
A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma GroupG M Smith, J A Child, M H Cullen, et al.
Seminars in Oncology|October 1, 1995
Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactionsA H Calvert, A Boddy, N P Bailey, et al.
Seminars in Oncology|October 1, 1994
Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation studyA H Calvert, M J Lind, S Ghazal-Aswad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumorsI Rafi, A V Boddy, J A Calvete, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
A phase I and pharmacokinetic study of LY231514, the multitargeted antifolateA C McDonald, P A Vasey, L Adams, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 1998
Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma GroupN P Bailey, N S Stuart, E M Bessell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancerM J Lind, S Ghazal-Aswad, L Gumbrell, et al.
Pageof 1